Boston Scientific Closes Multibillion-Dollar BTG Deal
Executive Summary
You may also be interested in...
Boston Scientific Agrees To Pay $4.2Bn For UK Interventional Oncology Firm BTG
A busy year of M&A for Boston Scientific just got busier with a $4.2bn cash offer for UK interventional medicine specialist BTG. Completion is expected by mid-year 2019.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.